Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats

Journal of the Peripheral Nervous System

Volumn 10, Issue 3, 2005, Pages 301-310

  Balayssac, David ^a,e   Cayre, Anne ^b   Authier, Nicolas ^a   Bourdu, Sophie ^c   Penault Llorca, Frederique ^b   Gillet, Jean Pierre ^d   Maublant, Jean ^b   Eschalier, Alain ^c   Coudore, François ^a  

^a Faculties of Medicine and Pharmacy   (France)

^b Jean Perrin Cancer Center   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d Research Center   (France)

^e Faculty of Dentistry   (France)

Author keywords

99mTc sestamibi; mdr1a; mdr1b; Neuropathy; Vincristine

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN P; MANNITOL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; RADIOPHARMACEUTICAL AGENT; RNA; VINCRISTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENE; GENE EXPRESSION; HISTOPATHOLOGY; MDR1A GENE; MDR1B GENE; MRP1 GENE; MRP2 GENE; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENES, MDR; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NERVOUS SYSTEM; ORGANOTECHNETIUM COMPOUNDS; P-GLYCOPROTEIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL EXAMINATION; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TIME FACTORS; VINCRISTINE;

EID: 27644433477     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1085-9489.2005.10308.x     Document Type: Article

References (49)

1. Allt G, Lawrenson JG (2000). The blood-nerve barrier: enzymes, transporters and receptors - a comparison with the blood-brain barrier. Brain Res Bull 52:1-12.
2. Arvidson B, Tjalve H (1985). Distribution of 109Cd in the nervous system of rats after intravenous injection. J Environ Pathol Toxicol Oncol 6:233-240.
3. Asbury AK (2000). Diseases of the peripheral nervous system. In: Harrison's Principles of Internal Medicine. Harrison TR (Ed). McGraw Hill International, London, pp 2835-2852.
4. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2003). A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 24:797-805.
5. Beck JF, Brugger D, Brischwein K, Liu C, Bader P, Niethammer D, Gekeler V (2001). Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias. Jpn J Cancer Res 92:896-903.
6. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD (2002). Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30:838-844.
7. Castle MC, Margileth DA, Oliverio VT (1976). Distribution and excretion of (3H) vincristine in the rat and the dog. Cancer Res 36:3684-3689.
8. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD (2002). Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97-104.
9. Cisternino S, Rousselle C, Lorico A, Rappa G, Scherrmann JM (2003). Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. Pharm Res 20:904-909.
10. Conrad S, Viertelhaus A, Orzechowski A, Hoogstraate J, Gjellan K, Schrenk D, Kauffmann HM (2001). Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology 156:81-91.
11. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
12. Dallel R, Voisin D (2001). Towards a pain treatment based on the identification of the pain-generating mechanisms? Eur Neurol 45:126-132.
13. de Lange EC (2004). Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 56:1793-1809.
14. Grubbs F (1969). Procedures for detecting outlying observations in samples. Technometrics 11:1-21.
15. Gupta RS (1988). Intrinsic multidrug resistance phenotype of Chinese hamster (rodent) cells in comparison to human cells. Biochem Biophys Res Commun 153:598-605.
16. Hendrikse NH, Franssen EJ, van der Graaf WT, Meijer C, Piers DA, Vaalburg W, de Vries EG (1998). 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated rotein. Br J Cancer 77:353-358.
17. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC (2001). The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res 61:1469-1476.
18. Kartner N, Riordan JR, Ling V (1983). Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288.
19. Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS (2002). Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 94:1815-1820.
20. Lotsch J, Schmidt R, Vetter G, Schmidt H, Niederberger E, Geisslinger G, Tegeder I (2002). Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 83:241-248.
21. Maublant J, de Latour M, Mestas D, Clemenson A, Charrier S, Feillel V, Le Bouedec G, Kaufmann P, Dauplat J, Veyre A (1996). Technetium-99m-sestamibi uptake in breast tumor and associated lymph nodes. J Nucl Med 37:922-925.
22. Maublant JC, Gachon P, Moins N (1988). Hexakis (2-methoxy isobutylisonitrile) technetium-99m and thallium-201 chloride: uptake and release in cultured myocardial cells. J Nucl Med 29:48-54.
23. Merimsky O, Loewenstein A, Chaitchik S (1992). Cortical blindness - a catastrophic side effect of vincristine. Anticancer Drugs 3:371-373.
24. Necker R, Hellon RF (1978). Noxious thermal input from the rat tail: modulation by descending inhibitory influences. Pain 4:231-242.
25. Olsson Y (1975). Vascular permeability in the peripheral nervous system. In: Peripheral Neuropathy. Dyck PJ, Thomas PK, Lambert EH (Eds). Saunders, Philadelphia, pp 190-200.
26. Perry JR, Warner E (1996). Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 46:1596-1599.
27. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM (1993). Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-984.
28. Potschka H, Fedrowitz M, Loscher W (2002). P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 327:173-176.
29. Quasthoff S, Hartung HP (2002). Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17.
30. Randall LO, Selitto JJ (1957), A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111:409-419.
31. Ray M, Marwaha RK, Trehan A (2002). Chemotherapy related fatal neurotoxicity during induction in acute lymphoblastic leukemia. Indian J Pediatr 69:185-187.
32. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, Roux F (1998). Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705-715.
33. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, Samanin R, Vezzani A (2002). Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 22:5833-5839.
34. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000). Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
35. Saito T, Zhang ZJ, Ohtsubo T, Noda I, Tokuriki M, Shibamori Y, Yamamoto T, Saito H (2004). Inhibitory effect of cyclosporin A on p-glycoprotein function in peripheral nerves of mice treated with doxorubicin and vinblastine. Acta Otolaryngol 124:313-317.
36. Saito T, Zhang ZJ, Shibamori Y, Ohtsubo T, Noda I, Yamamoto T, Saito H (1997). P-glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood-nerve barrier sites. Neurosci Lett 232:41-44.
37. Salphati L, Benet LZ (1998). Modulation of P-glycoprotein expression by cytochrome P450, 3A inducers in male and female rat livers. Biochem Pharmacol 55:387-395.
38. Scheithauer W, Ludwig H, Maida E (1985). Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Invest New Drugs 3:315-318.
39. Schinkel AH, Jonker JW (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
40. Stefansky W (1972). Rejecting outliers in factorial designs. Technometrics 14:469-479.
41. Sukhai M, Piquette-Miller M (2000). Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 3:268-280.
42. Sun H, Dai H, Shaik N, Elmquist WF (2003). Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83-105.
43. Tiberghien F, Loor F (1996). Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 7:568-578.
44. Topp KS, Tanner KD, Levine JD (2000). Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 424:563-576.
45. Uhr M, Grauer MT, Holsboer F (2003). Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54:840-846.
46. Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF, Ichise M (2000). Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 27:1786-1792.
47. van der Sandt IC, Gaillard PJ, Voorwinden HH, de Boer AG, Breimer DD (2001). P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm Res 18:587-592.
48. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC (1999). The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdrla (+/+) mice. Br J Pharmacol 128:563-568.
49. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.